Pulmonology Xagena
Moderate-to-severe asthma remains poorly treated. Researchers have evaluated the efficacy and safety of Dupilumab ( SAR231893 / REGN668 ), a fully human monoclonal antibody to the alpha subunit of the ...
Additional results from an interim analysis of a pivotal phase 2b study of Dupilumab in adult patients with moderate-to-severe asthma who are uncontrolled despite treatment with inhaled corticosteroid ...
Dupilumab ( Dupixent ), a fully human VelocImmune-derived anti-interleukin-4 ( IL-4 ) receptor alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, which are key drivers of type 2 inflamma ...